AVR Anteris Technologies

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

BRISBANE, Australia and EAGAN, Minn., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (ASX:AVR) (Anteris or the Company), a structural heart company advancing its novel DurAVR™ valve for aortic repair and replacement, today announced that Wayne Paterson, Chief Executive Officer, will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Friday, February 19, 2021 at 10:30AM ET.

About Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

For more information:

Jason Wong

Blueprint Life Science Group

E:

P: (415) 375-3340 Ext. 4



Twitter: @AnterisTech

Facebook: /AnterisTech



EN
16/02/2021

Underlying

AVRAnteris Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anteris Technologies

 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Announces Results for the First Quarter of 2025

Anteris Announces Results for the First Quarter of 2025 MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption (“IDE”) for the DurAVR® THV’s global, pivotal clinical trial (t...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Reaches Clinical Milestone: 100 patients treated ...

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, mar...

March 31, 2025 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Anteris Reports One-Year Patient Outcomes for DurAVR® THV New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR® Transcatheter Heart Valve (THV) Sys...

March 21, 2025 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Reports 2024 Financial Results and Provides Corporate Update EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2024, and provided a corporate update. 2024 Full Year Highlights & Recent Developments Achieved a successful U.S. Initial Public Offering (“IPO”...

March 13, 2025 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris to Present at Healthcare Investor Conferences - TD Cowen and B...

Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Anteris® Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a structural heart company developing DurAVR® THV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference. The details of each conference a...

February 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch